← Leaderboards
Yoshikazu Takada
Scripps Research Institute
$4,394,224
Attributed
$4,394,224
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $537.8K · FY2005–12$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$4,394,224 · 9
By mechanism
R01$3,168,315 · 3
U19$763,944 · 1
R21$336,059 · 1
P51$125,906 · 4
Top collaborators
No co-investigators on record.
Most similar at Scripps Research Institute
Same institution · by research overlap
- Christoph Rader$8,681,262
- David D Schlaepfer$17,083,110
- Carlos Ariel Guerrero$279,552
- Harry B Gray$6,032,852
- Erik J. Sorensen$6,556,102
Others in their field
Top investigators on “Integrins”
- Timothy A Springer · Boston Children'S Hospital$50,095,849
- David A Cheresh · Scripps Research Institute$28,587,859
- Mark Howard Ginsberg · University Of California, San Diego$28,221,483
- Martin A. Schwartz · Yale University$23,274,443
- M. Amin Arnaout · Massachusetts General Hospital$23,064,887
- Edward Franklin Plow · Cleveland Clinic Foundation$22,902,830
Research focus
IntegrinsBinding SitesBinding (Molecular Function)MutantIn VitroLigandsTumor GrowthPlayCell TypeSignal TransductionEndothelial CellsInflammationAffectCellsAngiogenesisResearch StudyCell AdhesionProtein Structure FunctionSpecificityCancer CellNeoplastic CellRecombinant ProteinsIntermolecular InteractionSite Directed Mutagenesis
Grant awards (22)
Potential of a dominant-negative FGF mutant as a therapeutic in cancer$309,376
R01 · FY2012 · CA · contact PI
Potential of a dominant-negative FGF mutant as a therapeutic in cancer$308,370
R01 · FY2011 · CA · contact PI
POTENTIAL OF NOVEL ANTI-INFLAMMATORY AGENTS TO SUPPRESS CHRONIC INFLAMMATION$25,210
P51 · FY2011 · RR · contact PI
Potential of a dominant-negative FGF mutant as a therapeutic in cancer$317,475
R01 · FY2010 · CA · contact PI
POTENTIAL OF NOVEL ANTI-INFLAMMATORY AGENTS TO SUPPRESS CHRONIC INFLAMMATION$37,989
P51 · FY2010 · RR · contact PI
Potential of a dominant-negative FGF mutant as a therapeutic in cancer$316,783
R01 · FY2009 · CA · contact PI
Characterization of Targeting Ligands-Integrin Interaction and in vitro targeting$185,430
U19 · FY2009 · CA · contact PI
POTENTIAL OF NOVEL ANTI-INFLAMMATORY AGENTS TO SUPPRESS CHRONIC INFLAMMATION$35,596
P51 · FY2009 · RR · contact PI
Characterization of Targeting Ligands-Integrin Interaction and in vitro targeting$179,480
U19 · FY2008 · CA · contact PI
POTENTIAL OF NOVEL ANTI-INFLAMMATORY AGENTS TO SUPPRESS CHRONIC INFLAMMATION$27,111
P51 · FY2008 · RR · contact PI
Integrins and the proinflammatory phospholipase A2$211,795
R21 · FY2007 · AG · contact PI
Characterization of Targeting Ligands-Integrin Interaction and in vitro targeting$174,760
U19 · FY2007 · CA · contact PI
Integrins and the proinflammatory phospholipase A2$124,264
R21 · FY2006 · AG · contact PI
Characterization of Targeting Ligands-Integrin Interaction and in vitro targeting$113,794
U19 · FY2006 · CA · contact PI
Characterization of Targeting Ligands-Integrin Interaction and in vitro targeting$110,480
U19 · FY2005 · CA
Role of Integrins in uPA/uPAR Signaling$237,600
R01 · FY2004 · GM
Role of Integrins in uPA/uPAR Signaling$237,600
R01 · FY2003 · GM
I-DOMAIN CONTAINING INTEGRIN/LIGAND INTERACTIONS$305,087
R01 · FY2002 · GM
Role of Integrins in uPA/uPAR Signaling$296,320
R01 · FY2002 · GM
Role of Integrins in uPA/uPAR Signaling$283,680
R01 · FY2001 · GM
I-DOMAIN CONTAINING INTEGRIN/LIGAND INTERACTIONS$282,068
R01 · FY2001 · GM
I-DOMAIN CONTAINING INTEGRIN/LIGAND INTERACTIONS$273,956
R01 · FY2000 · GM